Amount of potential cash payments that could result from the contingent consideration arrangement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

COMMITMENTS AND CONTINGENCIES (Details 2)	Dec. 31, 2011 Valeant Pharmaceuticals International ("Valeant") USD ($)	Dec. 31, 2011 Aton Pharma, Inc. ("Aton") USD ($)	Dec. 31, 2011 PharmaSwiss S.A. USD ($)	Dec. 31, 2011 PharmaSwiss S.A. EUR (€)	Dec. 31, 2011 iNova USD ($)
Other commitments
Milestone payments in terms of collaboration and license agreements	$ 390,000,000	$ 412,200,000
Potential contingent consideration payment			$ 13,000,000	€ 10,000,000	$ 59,900,000